Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

Abstract Background Predictive biomarkers are needed to identify oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER + /HER2-) metastatic breast cancer (MBC) patients who would likely benefit from cyclin-dependent kinase 4 and 6 inhibitors combined with endocrine thera...

Full description

Bibliographic Details
Main Authors: Cheng Liu, Shihui Hu, Xiaoping Xu, Yongping Zhang, Biyun Wang, Shaoli Song, Zhongyi Yang
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Breast Cancer Research
Subjects:
18F-FES
Tumour heterogeneity
Palbociclib
Endocrine therapy
Metastatic breast cancer
Online Access:https://doi.org/10.1186/s13058-022-01555-7

Internet

https://doi.org/10.1186/s13058-022-01555-7

Similar Items